Chronic Kidney Disease (Chronic Renal Failure) - Pipeline Review, H1 2018

  • ID: 4529324
  • Drug Pipelines
  • 219 pages
  • Global Markets Direct
1 of 5

FEATURED COMPANIES

  • Angion Biomedica Corp
  • Bayer AG
  • CTI BioPharma Corp
  • GNI Group Ltd
  • OPKO Health Inc
  • Resverlogix Corp
  • MORE
Chronic Kidney Disease (Chronic Renal Failure) - Pipeline Review, H1 2018

Summary:

This latest Pharmaceutical and Healthcare disease pipeline guide Chronic Kidney Disease (Chronic Renal Failure) - Pipeline Review, H1 2018, provides an overview of the Chronic Kidney Disease (Chronic Renal Failure) (Genito Urinary System And Sex Hormones) pipeline landscape.

Chronic kidney disease is the slow loss of kidney function over time. Signs and symptoms of kidney disease include nausea, vomiting, loss of appetite, fatigue and weakness, sleep problems, hiccups and swelling of feet and ankles. The predisposing factors include age, diabetes, high blood pressure, heart disease, smoking, obesity and high cholesterol.

Report Highlights:

This latest pipeline guide Chronic Kidney Disease (Chronic Renal Failure) - Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Chronic Kidney Disease (Chronic Renal Failure) (Genito Urinary System And Sex Hormones), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Chronic Kidney Disease (Chronic Renal Failure) (Genito Urinary System And Sex Hormones) pipeline guide also reviews of key players involved in therapeutic development for Chronic Kidney Disease (Chronic Renal Failure) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 1, 4, 8, 16, 1, 22 and 4 respectively. Similarly, the Universities portfolio in Phase II and Preclinical stages comprises 1 and 1 molecules, respectively.

Chronic Kidney Disease (Chronic Renal Failure) (Genito Urinary System And Sex Hormones) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Chronic Kidney Disease (Chronic Renal Failure) (Genito Urinary System And Sex Hormones).
  • The pipeline guide reviews pipeline therapeutics for Chronic Kidney Disease (Chronic Renal Failure) (Genito Urinary System And Sex Hormones) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Chronic Kidney Disease (Chronic Renal Failure) (Genito Urinary System And Sex Hormones) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Chronic Kidney Disease (Chronic Renal Failure) (Genito Urinary System And Sex Hormones) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Chronic Kidney Disease (Chronic Renal Failure) (Genito Urinary System And Sex Hormones)
Reasons for Purchase:
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Chronic Kidney Disease (Chronic Renal Failure) (Genito Urinary System And Sex Hormones).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Chronic Kidney Disease (Chronic Renal Failure) (Genito Urinary System And Sex Hormones) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Angion Biomedica Corp
  • Bayer AG
  • CTI BioPharma Corp
  • GNI Group Ltd
  • OPKO Health Inc
  • Resverlogix Corp
  • MORE
Introduction

Chronic Kidney Disease (Chronic Renal Failure) - Overview

Chronic Kidney Disease (Chronic Renal Failure) - Therapeutics Development

Chronic Kidney Disease (Chronic Renal Failure) - Therapeutics Assessment

Chronic Kidney Disease (Chronic Renal Failure) - Companies Involved in Therapeutics Development

Chronic Kidney Disease (Chronic Renal Failure) - Drug Profiles

Chronic Kidney Disease (Chronic Renal Failure) - Dormant Projects

Chronic Kidney Disease (Chronic Renal Failure) - Discontinued Products

Chronic Kidney Disease (Chronic Renal Failure) - Product Development Milestones

Appendix

List of Tables

Table 1: Number of Products under Development for Chronic Kidney Disease (Chronic Renal Failure), H1 2018

Table 2: Number of Products under Development by Companies, H1 2018

Table 3: Number of Products under Development by Companies, H1 2018 (Contd..1), H1 2018

Table 4: Number of Products under Development by Companies, H1 2018 (Contd..2), H1 2018

Table 5: Number of Products under Development by Universities/Institutes, H1 2018

Table 6: Products under Development by Companies, H1 2018

Table 7: Products under Development by Companies, H1 2018 (Contd..1), H1 2018

Table 8: Products under Development by Companies, H1 2018 (Contd..2), H1 2018

Table 9: Products under Development by Companies, H1 2018 (Contd..3), H1 2018

Table 10: Products under Development by Universities/Institutes, H1 2018

Table 11: Number of Products by Stage and Target, H1 2018

Table 12: Number of Products by Stage and Target, H1 2018 (Contd..1), H1 2018

Table 13: Number of Products by Stage and Mechanism of Action, H1 2018

Table 14: Number of Products by Stage and Mechanism of Action, H1 2018 (Contd..1), H1 2018

Table 15: Number of Products by Stage and Route of Administration, H1 2018

Table 16: Number of Products by Stage and Molecule Type, H1 2018

Table 17: Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Allena Pharmaceuticals Inc, H1 2018

Table 18: Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Angion Biomedica Corp, H1 2018

Table 19: Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by apceth Biopharma GmbH, H1 2018

Table 20: Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Astellas Pharma Inc, H1 2018

Table 21: Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by AstraZeneca Plc, H1 2018

Table 22: Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Bayer AG, H1 2018

Table 23: Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Boehringer Ingelheim GmbH, H1 2018

Table 24: Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Boryung Pharmaceutical Co Ltd, H1 2018

Table 25: Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Cellmid Ltd, H1 2018

Table 26: Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Chugai Pharmaceutical Co Ltd, H1 2018

Table 27: Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Corvidia Therapeutics, H1 2018

Table 28: Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by CTI BioPharma Corp, H1 2018

Table 29: Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by DURECT Corp, H1 2018

Table 30: Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Evotec AG, H1 2018

Table 31: Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Gilead Sciences Inc, H1 2018

Table 32: Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by GNI Group Ltd, H1 2018

Table 33: Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Lupin Ltd, H1 2018

Table 34: Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Navya Biologicals Pvt Ltd, H1 2018

Table 35: Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Novartis AG, H1 2018

Table 36: Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by OPKO Health Inc, H1 2018

Table 37: Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Otsuka Holdings Co Ltd, H1 2018

Table 38: Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Prolong Pharmaceuticals LLC, H1 2018

Table 39: Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by ProMetic Life Sciences Inc, H1 2018

Table 40: Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Reata Pharmaceuticals Inc, H1 2018

Table 41: Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Relypsa Inc, H1 2018

Table 42: Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Resverlogix Corp, H1 2018

Table 43: Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Rockwell Medical Inc, H1 2018

Table 44: Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Sanwa Kagaku Kenkyusho Co Ltd, H1 2018

Table 45: Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Sarfez Pharmaceuticals Inc, H1 2018

Table 46: Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Taisho Pharmaceutical Holdings Co Ltd, H1 2018

Table 47: Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Toray Industries Inc, H1 2018

Table 48: Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Tricida Inc, H1 2018

Table 49: Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Unity Biotechnology Inc, H1 2018

Table 50: Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Vascular BioSciences, H1 2018

Table 51: Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by VESSL Therapeutics Ltd, H1 2018

Table 52: Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Vicore Pharma AB, H1 2018

Table 53: Chronic Kidney Disease (Chronic Renal Failure) - Dormant Projects, H1 2018

Table 54: Chronic Kidney Disease (Chronic Renal Failure) - Dormant Projects, H1 2018 (Contd..1), H1 2018

Table 55: Chronic Kidney Disease (Chronic Renal Failure) - Dormant Projects, H1 2018 (Contd..2), H1 2018

Table 56: Chronic Kidney Disease (Chronic Renal Failure) - Discontinued Products, H1 2018

List of Figures

Figure 1: Number of Products under Development for Chronic Kidney Disease (Chronic Renal Failure), H1 2018

Figure 2: Number of Products under Development by Companies, H1 2018

Figure 3: Number of Products under Development by Universities/Institutes, H1 2018

Figure 4: Number of Products by Top 10 Targets, H1 2018

Figure 5: Number of Products by Stage and Top 10 Targets, H1 2018

Figure 6: Number of Products by Top 10 Mechanism of Actions, H1 2018

Figure 7: Number of Products by Stage and Top 10 Mechanism of Actions, H1 2018

Figure 8: Number of Products by Top 10 Routes of Administration, H1 2018

Figure 9: Number of Products by Stage and Top 10 Routes of Administration, H1 2018

Figure 10: Number of Products by Top 10 Molecule Types, H1 2018

Figure 11: Number of Products by Stage and Top 10 Molecule Types, H1
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • Allena Pharmaceuticals Inc
  • Angion Biomedica Corp
  • apceth Biopharma GmbH
  • Astellas Pharma Inc
  • AstraZeneca Plc
  • Bayer AG
  • Boehringer Ingelheim GmbH
  • Boryung Pharmaceutical Co Ltd
  • Cellmid Ltd
  • Chugai Pharmaceutical Co Ltd
  • Corvidia Therapeutics
  • CTI BioPharma Corp
  • DURECT Corp
  • Evotec AG
  • Gilead Sciences Inc
  • GNI Group Ltd
  • Lupin Ltd
  • Navya Biologicals Pvt Ltd
  • Novartis AG
  • OPKO Health Inc
  • Otsuka Holdings Co Ltd
  • Prolong Pharmaceuticals LLC
  • ProMetic Life Sciences Inc
  • Reata Pharmaceuticals Inc
  • Relypsa Inc
  • Resverlogix Corp
  • Rockwell Medical Inc
  • Sanwa Kagaku Kenkyusho Co Ltd
  • Sarfez Pharmaceuticals Inc
  • Taisho Pharmaceutical Holdings Co Ltd
  • Toray Industries Inc
  • Tricida Inc
  • Unity Biotechnology Inc
  • Vascular BioSciences
  • VESSL Therapeutics Ltd
  • Vicore Pharma AB
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll